News

Life Sciences

Tango Therapeutics Signs Immuno-Oncology Collaboration with Gilead

Edward Kim | Equities.com |

$50 million upfront + up to $1.7 billion in milestone payments (Image: Tango Therapeutics)


Orchard Therapeutics' $200 Million IPO Expected This Week for Gene Therapy Programs

Edward Kim | Equities.com |

Autologous gene therapy for rare diseases including primary immune deficiencies, inherited metabolic disorders and blood disorders (Image: Orchard Therapeutics).


Dicerna Signs Potential Multi Billion Dollar Licensing and Research Deal with Lilly

Edward Kim | Equities.com |

$100 million upfront + $100 million in equity + up to $350 million in milestone payments per target for at least 10 targets (Image: Dicerna Pharmaceuticals)


Twist Bioscience's $75 Million IPO Expected Next Week for Gene Synthesis Platform

Edward Kim | Equities.com |

"Writing" synthetic DNA on silicon chips. Synthetic biology products market expected to grow to $13.9 billion by 2022 (Image: Twist Bioscience)


Shionogi and Roche Get FDA Approval for First New Flu Drug in Nearly 20 Years

Edward Kim | Equities.com |

New oral treatment to supplement vaccination, which remains the primary means of flu prevention (Image: CBS News)


Proteostasis Raises $74 Million in Follow-on Offering After Positive Cystic Fibrosis Data

Edward Kim | Equities.com |

Positive preliminary results from all cohorts of combination Phase 1 study (Image: Proteostasis Therapeutics)


Stoke Therapeutics Raises $90 Million Series B for Therapies to Restore Gene Expression

Edward Kim | Equities.com |

Antisense oligonucleotide therapies to increase gene expression for the treatment of severe genetic diseases. Lead candidate in Dravet Syndrome (Image: Stoke Therapeutics).


Gamida Cell's $50 Million IPO Expected This Week for Blood Cancers

Edward Kim | Equities.com |

Currently enrolling Phase 3 patients for cord blood cell therapy with potential to be universal curative stem cell graft (Image: Gamida Cell)


Clovis Oncology Shows Positive Initial Phase 2 Data in Prostate Cancer

Edward Kim | Equities.com |

44% confirmed objective response rate in metastatic castration resistant prostate cancer. Rubraca (rucaparib) is FDA approved as maintenance treatment for ovarian cancer. (Image: Clovis Oncology)


LogicBio's $75 Million IPO Expected This Week for Rare Disease Gene Therapy

Edward Kim | Equities.com |

Genome editing technology, Initially targeting rare liver disorders in pediatric patients (Image: LogicBio).


Emerging Growth

DirectView Holdings Inc

DirectView Holdings Inc designs and installs surveillance systems, digital video recording and services. The company through its subsidiaries operates within two divisions security and surveillance and video conferencing services.

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more